Dihydroergotamine Nasal Spray

Major

Dihydroergotamine Nasal Spray Lumacaftor Reduced exposure to CYP3A substrate Details Dihydroergotamine Nasal Spray Mavorixafor Xolremdi Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Dihydroergotamine Nasal Spray Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Dihydroergotamine Nasal Spray Mitotane Lysodren Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI exposure Details Dihydroergotamine Nasal Spray Mobocertinib Exkivity Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Dihydroergotamine Nasal Spray Netupitant Increased exposure of CYP3A4 substrate Details Dihydroergotamine Nasal Spray Nilotinib Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Nirogacestat Ogsiveo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Dihydroergotamine Nasal Spray Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Dihydroergotamine Nasal Spray Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Dihydroergotamine Nasal Spray Pacritinib Vonjo® Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Dihydroergotamine Nasal Spray Palbociclib Ibrance Increased exposure to CYP3A substrates with a narrow therapeutic index Details Dihydroergotamine Nasal Spray Pazopanib Votrient Increased dihydroergotamine concentrations and risk of ergot toxicity Details Dihydroergotamine Nasal Spray Phenobarbital Fidoquel Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Nasal Spray Pirtobrutinib Jaypirca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Dihydroergotamine Nasal Spray Primidone Mysoline Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Nasal Spray Propatyl Nitrate Increased risk of ergotism Details Dihydroergotamine Nasal Spray Propranolol Hemangeol Increased risk of coronary artery vasospasm Details Dihydroergotamine Nasal Spray Ranolazine Aspruzyo Increased exposure of CYP3A4 substrate Details Dihydroergotamine Nasal Spray Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Dihydroergotamine Nasal Spray Repotrectinib Augtyro Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Dihydroergotamine Nasal Spray Ritlecitinib Litfulo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Dihydroergotamine Nasal Spray Schizandra Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Selpercatinib Retevmo Increased substrate exposure and an increased risk for adverse effects Details Dihydroergotamine Nasal Spray Sevabertinib Hyrnuo Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Dihydroergotamine Nasal Spray Sibutramine An increased risk of serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes) Details Dihydroergotamine Nasal Spray Sotorasib Lumakras Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Dihydroergotamine Nasal Spray Stiripentol Diacomit Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Suzetrigine Journavx Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Dihydroergotamine Nasal Spray Taurursodiol Decreased exposure of the CYP3A4 substrate Details Dihydroergotamine Nasal Spray Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Nasal Spray Tocilizumab Actemra Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Dihydroergotamine Nasal Spray Tovorafenib Ojemda Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Dihydroergotamine Nasal Spray Treosulfan Grafapex Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse and serious life-threatening toxicit... Details Dihydroergotamine Nasal Spray Verapamil Calan Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Vonoprazan Voquezna Increased CYP3A substrates exposure Details Dihydroergotamine Nasal Spray Vorasidenib Voranigo Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Dihydroergotamine Nasal Spray Voxelotor Oxbryta Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Zileuton Zyflo Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details